AstraZeneca reported that the company’s Phase III KESTREL trial of Imfinzi (durvalumab) failed to meet the primary endpoint of improving overall survival compared to the EXTREME treatment regimen, which was chemotherapy plus cetuximab, a standard of care.
In honor of World Cancer Day, FCB Health Network announced “The Trial for #ClinicalEquality,” an initiative dedicated to achieving racial equity in clinical trials.
Roche presented updated data confirming the Swiss drugmaker’s immunotherapy Tecentriq, used in combination with Avastin, substantially improves overall survival in people with the most common form of liver cancer.
Life sciences mergers and acquisitions (M&A) activity totaled $159 billion in 2020, down from $306 billion in 2019, reaching one of the lowest levels since 2014, according to the 2021 EY M&A Firepower report
New Data Reinforce Long-Term Benefit of Venclexta-Based Combination for Relapsed or Refractory CLL
American Society of Hematology (ASH) Annual Meeting, Blockbusters, Chronic Lymphocytic Leukemia (CLL), Clinical Trials, Data, Minimal Residual Disease (MRD), Progression-Free Survival (PFS), R&D, TherapeuticsRoche Group member Genentech announced that new data from the pivotal Phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta (venetoclax)-based combinations in certain people with chronic lymphocytic leukemia (CLL) and provide more evidence on the potential value of minimal residual disease.
Immunocore’s Phase III IMCgp100-202 trial of tebentafusp compared to investigator’s choice for metastatic uveal melanoma (mUM) met the pre-defined boundaries for statistical significance of the primary endpoint of overall survival in its first pre-planned interim analysis.
Five Prime Therapeutics Inc., in collaboration Zai Lab Limited on the development of bemarituzumab – a novel therapy for front-line advanced non HER2+ gastric or gastroesophageal junction (GEJ) cancer – announced groundbreaking positive topline Phase II results.
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
Blockbusters, Clinical Data, Clinical Trials, Combination Therapies, Overall Response Rate (ORR), Overall Survival (OS), Primary Endpoints, Progression-Free Survival (PFS), R&D, Renal Cell Carcinoma (RCC), Secondary Endpoints, Therapeutics, Topline DataMerck and Eisai announced new investigational data demonstrating positive top-line results from the Phase III KEYNOTE-581/CLEAR trial (Study 307).
Langland announced the appointment of Angela Rochelle as Account Director, Head of Diversity Initiatives in Clinical Trials.
Denmark-based Genmab A/S announced positive topline data from the second part of the Phase III CASSIOPEIA trial evaluating daratumumab (marketed as Darzalex) monotherapy as maintenance treatment compared to observation for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.